Shire suffered a sell-off after the biotech giant raised concerns about its haemophilia treatments.
The FTSE 100 firm was reported to have revealed in an interview that its haemophilia treatments were at risk of being excluded from the list of covered medicines that insurers will pay out for.
It was also reported that it is considering ways to manage the rising costs of medicines for the condition so that patients aren’t forced to switch treatments.
This made investors nervous that Shire’s profits could be hit.
But analysts at Liberum said investors had overreacted and that prices for treatments will rise only around 2 per cent, considerably less than price rises in the past which have been in double digits.
It added: ‘[This overreaction] is particularly the case given the dearth of any detail over which haemophilia drugs could be affected.’